User profiles for Jelle Wesseling
Jelle WesselingGroup Leader, Netherlands Cancer Institute Verified email at nki.nl Cited by 21673 |
[HTML][HTML] Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis …
…, A Broeks, FE Van Leeuwen, J Wesseling… - PLoS …, 2010 - journals.plos.org
Background Immunohistochemical markers are often used to classify breast cancer into
subtypes that are biologically distinct and behave differently. The aim of this study was to …
subtypes that are biologically distinct and behave differently. The aim of this study was to …
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
…, C Robert, J Haanen, C Blank, J Wesseling… - Nature, 2014 - nature.com
Abstract Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target
the BRAF or MEK kinases can be effective, but resistance develops invariably 1 , 2 . In …
the BRAF or MEK kinases can be effective, but resistance develops invariably 1 , 2 . In …
[HTML][HTML] Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
…, TG Steenbruggen, M van Seijen, J Wesseling… - The Lancet …, 2022 - thelancet.com
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.
J Wesseling, SW van der Valk, HL Vos… - The Journal of cell …, 1995 - rupress.org
Episialin (MUC1) is a transmembrane molecule with a large mucin-like extracellular domain
protruding high above the cell surface. The molecule is located at the apical side of most …
protruding high above the cell surface. The molecule is located at the apical side of most …
[HTML][HTML] Personalized early detection and prevention of breast cancer: ENVISION consensus statement
The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer
(ENVISION) brings together several international research consortia working on different …
(ENVISION) brings together several international research consortia working on different …
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure
M Donker, ME Straver, J Wesseling, CE Loo… - Annals of …, 2015 - journals.lww.com
Objective: The MARI procedure [marking the axillary lymph node with radioactive iodine (125
I) seeds] is a new minimal invasive method to assess the pathological response of nodal …
I) seeds] is a new minimal invasive method to assess the pathological response of nodal …
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.
J Wesseling, SW van der Valk… - Molecular biology of the …, 1996 - Am Soc Cell Biol
Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated
glycoprotein with an extended mucin-like ectodomain. This domain mainly consists of 30-90 …
glycoprotein with an extended mucin-like ectodomain. This domain mainly consists of 30-90 …
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
Mutations in the chromatin remodeling gene ARID1A have recently been identified in the
majority of ovarian clear cell carcinomas (OCCCs). To determine the prevalence of mutations in …
majority of ovarian clear cell carcinomas (OCCCs). To determine the prevalence of mutations in …
[PDF][PDF] Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype
…, ME Straver, S Rodenhuis, SH Muller, J Wesseling… - J clin …, 2011 - researchgate.net
… Rodenhuis, Jelle Wesseling, Marie-Jeanne TFD Vrancken Peeters Collection and
assembly of data: Claudette E. Loo, Marieke E. Straver, Jelle Wesseling, Kenneth GA …
assembly of data: Claudette E. Loo, Marieke E. Straver, Jelle Wesseling, Kenneth GA …
[HTML][HTML] Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low …
…, RM Pijnappel, N Bijker, J Emiel, J Wesseling - European journal of …, 2015 - Elsevier
Background The current debate on overdiagnosis and overtreatment of screen-detected
ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A …
ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A …